Analyst Price Targets — NUVL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 24, 2025 12:25 pm | — | Truist Financial | $140.00 | $105.88 | TheFly | Nuvalent initiated with a Buy at Truist |
| November 17, 2025 6:25 pm | Etzer Darout | Barclays | $152.00 | $108.00 | TheFly | Nuvalent price target raised to $152 from $112 at Barclays |
| November 17, 2025 4:23 pm | — | Leerink Partners | $149.00 | $110.56 | TheFly | Nuvalent price target raised to $149 from $140 at Leerink |
| November 17, 2025 1:48 pm | — | H.C. Wainwright | $155.00 | $110.60 | TheFly | Nuvalent price target raised to $155 from $130 at H.C. Wainwright |
| November 12, 2025 11:36 am | — | Canaccord Genuity | $126.00 | $96.16 | TheFly | Canaccord starts 'best-in-class' Nuvalent with Buy rating |
| October 31, 2025 1:26 pm | — | Goldman Sachs | $120.00 | $98.17 | TheFly | Nuvalent price target raised to $120 from $105 at Goldman Sachs |
| October 31, 2025 10:03 am | David Dai | UBS | $132.00 | $98.17 | StreetInsider | Nuvalent (NUVL) PT Raised to $132 at UBS |
| October 27, 2025 10:55 am | Kelsey Goodwin | Piper Sandler | $128.00 | $93.39 | TheFly | Nuvalent price target raised to $128 from $112 at Piper Sandler |
| October 15, 2025 1:27 pm | Josh Schimmer | Cantor Fitzgerald | $135.00 | $89.35 | TheFly | Nuvalent initiated with an Overweight at Cantor Fitzgerald |
| September 3, 2025 8:26 pm | — | Guggenheim | $122.00 | $79.54 | TheFly | Nuvalent assumed with a Buy at Guggenheim |
Latest News for NUVL
Zidesamtinib demonstrated meaningful clinical activity in subset of TKI pre-treated ROS1-positive NSCLC patients from ARROS-1 trial previously treated with repotrectinib or taletrectinib, including in those with CNS disease or ROS1 resistance mutations Preclinical data support differentiated brain penetrance and intracranial activity as compared to repotrectinib and taletrectinib CAMBRIDGE, Mass., April 17, 2026…
New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trial CAMBRIDGE, Mass., April 7, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the submission to the U.S. Food and Drug Administration (FDA) of…
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) CFO Alexandra Balcom sold 11,430 shares of Nuvalent stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $105.21, for a total transaction of $1,202,550.30. Following the transaction, the chief financial officer owned 85,533 shares in the company, valued at approximately
CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new data for zidesamtinib, an investigational ROS1-selective inhibitor, during two poster presentations at the American Association for Cancer Research (AACR)…
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the sixteen research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and fifteen have assigned a buy recommendation to the company. The average 12 month price
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NUVL.
U.S. House Trading
No House trades found for NUVL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.